Newsletter Subject

Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Fri, Oct 20, 2023 10:52 PM

Email Preheader Text

Daily Headlines Friday, October 20, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT

[MEDPAGE TODAY]( Daily Headlines Friday, October 20, 2023 Today's Top Stories for {NAME} [MEETING COVERAGE]( [Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer]( [PULMONOLOGY]( [Fancy Nasal Suction Device Makes Little Difference in Infant Bronchiolitis]( [PRACTICE MANAGEMENT]( [House Members Mull Bills to Cut Red Tape and Improve Docs' Medicare Pay]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Incorporating Recent Data Into Current Treatment Paradigms in Melanoma]( [SPECIAL REPORTS]( [Kids Specializing in One Sport More at Risk for Injury and Burnout, Experts Say]( [GASTROENTEROLOGY]( [Old Antidepressant Eases Irritable Bowel Syndrome Symptoms]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [MEETING COVERAGE]( [Untreated, New-Onset Hypertension Tied to Fibroid Development in Midlife]( CME SPOTLIGHT [Uncovering the Underlying Cause of Anemia: Making a Myelodysplastic Syndrome Diagnosis]( [AAD READING ROOM]( [CAL/BDP Cream Effective for Plaque Psoriasis in Patients With Skin of Color]( [PUBLIC HEALTH & POLICY]( [Should Scientists Openly Debate Vaccine Policies?]( [MEETING COVERAGE]( [Sperm Banks Lack Diverse Donors for Diverse Recipients]( CME SPOTLIGHT [Optimizing Anemia Management in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia Through Shared Decision-Making]( [ASCO READING ROOM]( [Hiroaki Akamatsu, MD, PhD, on Add-On KRAS G12C Inhibition in Advanced NSCLC]( [ASCO READING ROOM]( [Real-World Study of Sotorasib in KRAS G12C-Mutant NSCLC May Help in Treatment Decision-Making]( [IDSA READING ROOM]( [From Needles to Nets: Exploring Malaria Prevention]( CME SPOTLIGHT [Individualizing Treatment to Advance Integration of New Evidence and Quality Care in von Willebrand Disease]( [PODCASTS]( [Breaking Point: Why We Become Activists]( [PODCASTS]( [Telling My Story at the National Nurses March]( [PODCASTS]( [Nurse Sees Other Side of Unsafe Staffing]( CME SPOTLIGHT [Navigating the Rapidly Evolving DLBCL Treatment Landscape to Deliver Quality Care]( [PODCASTS]( [From New Pandemic Resident to Union Advocate]( [MEDICAL JOURNEYS]( [For Your Patients: Talking to Your Doctor About Osteoporosis]( [MEDICAL JOURNEYS]( [Case Study: What Made This Cardiomyopathy Patient's Myocardial Bridge Worsen After PTSMA Treatment?]( CME SPOTLIGHT [Advancing cTTP Care Through Integration of the Latest Clinical Evidence]( # Weekly Survey [Age Cutoff for Prostate Cancer Surveillance: Good or Bad?]( No consensus has been reached on when or whether men with [low-risk prostate cancer]( can stop active surveillance[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-10-20&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.